Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

@article{Jacobson2013SofosbuvirFH,
  title={Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.},
  author={Ira M Jacobson and Stuart C. Gordon and Kris V. Kowdley and Eric M Yoshida and Norman Gitlin and Mark S Sulkowski and Mitchell L. Shiffman and Eric Lawitz and Gregory Thomas Everson and Michael V. L. Bennett and Eugene R Schiff and Mohammed T Al-Assi and Gopinath M. Subramanian and Di An and Ming Fang Lin and John McNally and Diana M. Brainard and William T. Symonds and John McHutchison and Keyur A. Patel and Jordan J Feld and Stephen Pianko and David R Nelson},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 20},
  pages={
          1867-77
        }
}
BACKGROUND Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection. METHODS We conducted two randomized, phase 3 studies involving patients with chronic HCV… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 540 CITATIONS, ESTIMATED 39% COVERAGE

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Sofosbuvir, a Significant Paradigm Change in HCV Treatment

  • Journal of clinical and translational hepatology
  • 2015
VIEW 14 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Sofosbuvir: First Global Approval

VIEW 9 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
VIEW 8 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

EASL Recommendations on Treatment of Hepatitis C 2016.

  • Journal of hepatology
  • 2017
VIEW 4 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 67 Highly Influenced Citations

  • Averaged 44 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Once daily sofosbuvir (GS­7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial

EJ Gane, CA Stedman, RH Hyland
  • Hepatol­ ogy 2012;56:Suppl:306A­307A. abstract
  • 2012
VIEW 1 EXCERPT

Adverse effects of drugs in the treatment of viral hepatitis.

  • Best practice & research. Clinical gastroenterology
  • 2010
VIEW 2 EXCERPTS